论文信息 - Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. - 字舞流文

Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma.

J. Canon | J. Vansteenkiste | P. Vuylsteke | L. Decoster | E. Teugels | J. De Grève | T. Morán | M. Graas | D. Massey | D. Schallier | D. Galdermans | V. Chand